164 related articles for article (PubMed ID: 32419531)
1. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review.
Ghamrawi RI; Ghiam N; Wu JJ
J Dermatolog Treat; 2022 Feb; 33(1):94-99. PubMed ID: 32419531
[TBL] [Abstract][Full Text] [Related]
2. Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review.
Ghamrawi RI; Ghiam N; Wu JJ
J Dermatolog Treat; 2022 May; 33(3):1252-1256. PubMed ID: 32962478
[TBL] [Abstract][Full Text] [Related]
3. Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review.
Chat VS; Uppal SK; Kearns DG; Wu JJ
Dermatol Ther; 2021 Jul; 34(4):e14974. PubMed ID: 33991048
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
5. Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review.
Shah VV; Lee EB; Reddy S; Lin EJ; Wu JJ
J Dermatolog Treat; 2018 Sep; 29(6):586-592. PubMed ID: 29334280
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Takamura S; Sugai S; Taguchi R; Teraki Y
J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
[TBL] [Abstract][Full Text] [Related]
7. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review.
Kahn JS; Casseres RG; Her MJ; Dumont N; Gottlieb AB; Rosmarin D
J Drugs Dermatol; 2019 Apr; 18(4):. PubMed ID: 31013012
[TBL] [Abstract][Full Text] [Related]
9. Off-label studies on apremilast in dermatology: a review.
Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
[No Abstract] [Full Text] [Related]
10. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
Knuckles MLF; Levi E; Soung J
J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
[No Abstract] [Full Text] [Related]
11. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
12. Real-World Experience With Apremilast in Treating Psoriasis.
Mayba JN; Gooderham MJ
J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
14. The Use of Apremilast in Psoriasis: A Delphi Study.
Carrascosa JM; Belinchón I; Rivera R; Ara M; Bustinduy M; Herranz P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):115-134. PubMed ID: 31864537
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review.
Kearns DG; Uppal S; Chat VS; Wu JJ
J Clin Aesthet Dermatol; 2021 Jun; 14(6):55-59. PubMed ID: 34804357
[TBL] [Abstract][Full Text] [Related]
16. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
[No Abstract] [Full Text] [Related]
17. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Dressler C; Rosumeck S; Werner RN; van der Kraaij G; van Lumig P; Wakkee M; Spuls P; Nast A
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1964-1977. PubMed ID: 28944515
[No Abstract] [Full Text] [Related]
18. Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Biologics to clinical practice.
Pithadia DJ; Reynolds KA; Lee EB; Wu JJ
Cutis; 2019 Aug; 104(2S):12-16. PubMed ID: 31634385
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Guidelines for the Use of Cyclosporine for Psoriasis: A Critical Appraisal and Comprehensive Review.
Soleymani T; Vassantachart JM; Wu JJ
J Drugs Dermatol; 2016 Mar; 15(3):293-301. PubMed ID: 26954314
[TBL] [Abstract][Full Text] [Related]
20. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
